2026 Q2 - tulosraportti
34 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 056 | ||
| 99 427 | ||
| 90 000 | ||
| 270 000 | ||
| 270 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·Alle minuutti sittenWishing everyone a nice day and week, good luck with softox and otherwise in the stock market and life in general, a little patience and I think this stock will come like a shot, keep it up and good luck❤️💪🌞
·18 t sittenSoftOx has already completed an extensive preclinical program, including GLP safety studies in two animal species. Recent respiratory studies in the laboratory and animals have also been completed, and GMP production of study medication is established. There are thus several years of development work behind the current studies. SIS-02 in Ireland is investigating safety and tolerability in healthy volunteers and started dosing in June 2026. SIS-03 completed dose escalation the same month with no reported serious adverse events, and the first patient was dosed in August. The company expects data readouts from both studies in the first half of 2027. In addition, the company has been granted a US patent for the dry matter precursor and brought in Bruce Montgomery, with experience from TOBI and Cayston, as head of the clinical advisory committee. H1 2027 could be an important milestone where new human data are evaluated together with existing animal data, manufacturing and patent protection. Positive results could strengthen the basis for partnerships.
then we are on our way up towards 0.135 again, now there were no more stoplosses to fish for under 0.11, therefore today's great rise. gi seg selv en ørefik for at ikke man kjøpte flere aksjer igår.....- ·1 päivä sittenWhy sis02 in Ireland has come further than most people think. Before SoftOx started today's studies, the company conducted an extensive animal preclinical safety program (toxicology) with the first-generation solution SS0330. This included regulatory GLP studies (Good Laboratory Practice) in two animal species - Göttingen minipigs (up to 14 days with concentrations up to 200 micrograms/mL) and rats (up to 28 days with 1000 micrograms/mL). When a biotech company improves the formulation of a drug during development, a critical question always arises: Must one go back to square one and redo all the expensive and time-consuming animal safety studies, or can one build a scientific "bridge" that allows the company to reuse the work already done? In SoftOx, this bridge is about the transition from the first-generation solution (SS0330) to today's more stable second-generation solution (SS0331 / SIS 2.0). In December 2023, SoftOx obtained formal Scientific Advice from the Danish Medicines Agency (DKMA) to adapt the clinical and non-clinical strategy to this transition. They gave the green light, in addition, partners in the COUNTERACT consortium from summer 2024 have conducted new efficacy studies in the laboratory and in animals (respiratory tract models in mice and rats) with the second-generation solution, where the half-year report for 2026 (p. 22) confirms completed in vitro and in vivo respiratory studies before 2026. The reading of SIS-02 and SIS-03 in the first half of 2027 will therefore be a connection point for work already done, rather than the starting gun for an entirely new preclinical round. When in H1 2027 one gets the answer on which dose human lungs can tolerate in SIS-02 (after the dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.Fresh US patents and heavy FDA expertise in place Digging into American patent registers, one can see that SoftOx's wholly owned IP company WIAB Water Innovation AB has been granted several US patents in 2025–2026. Most interesting is US Patent 12,611,425 (issued April 28, 2026, applied for in August 2023 – the work was presented at the US military's MHSRS symposium in Florida). While current studies test the ready-mixed second-generation liquid (with over two years of shelf life), this patent covers a storage-stable dry-matter precursor (tablet/granulate dissolved in liquid right before use, providing active hypochlorous acid in seconds). For military emergency stockpiles and field use – where low weight and long shelf life without a cold chain are crucial – and for American industrial partners requiring solid IP protection in the US, this is an important piece. Adding together the completed preclinical work, GMP production, American patent protection, and last autumn's recruitment of Dr. Bruce Montgomery (the man who led the FDA-approved inhalation antibiotics TOBI® and Cayston® through approval and sale to Gilead) as head of the Clinical Advisory Board, "phase 1" becomes a far too narrow description of what has actually been built up. H1 2027 as a connection point – not a starting line My hypothesis is therefore that the readout of SIS-02 and SIS-03 in the first half of 2027 will be a connection point for work already performed, rather than the starting shot for an entirely new preclinical round. When the definitive answer to what dose human lungs can tolerate in SIS-02 is obtained in H1 2027 (after dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.
·1 päivä sittenWhen does this turn around? The bottom is well reached soon or?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·Alle minuutti sittenWishing everyone a nice day and week, good luck with softox and otherwise in the stock market and life in general, a little patience and I think this stock will come like a shot, keep it up and good luck❤️💪🌞
- ·18 t sittenSoftOx has already completed an extensive preclinical program, including GLP safety studies in two animal species. Recent respiratory studies in the laboratory and animals have also been completed, and GMP production of study medication is established. There are thus several years of development work behind the current studies. SIS-02 in Ireland is investigating safety and tolerability in healthy volunteers and started dosing in June 2026. SIS-03 completed dose escalation the same month with no reported serious adverse events, and the first patient was dosed in August. The company expects data readouts from both studies in the first half of 2027. In addition, the company has been granted a US patent for the dry matter precursor and brought in Bruce Montgomery, with experience from TOBI and Cayston, as head of the clinical advisory committee. H1 2027 could be an important milestone where new human data are evaluated together with existing animal data, manufacturing and patent protection. Positive results could strengthen the basis for partnerships.then we are on our way up towards 0.135 again, now there were no more stoplosses to fish for under 0.11, therefore today's great rise. gi seg selv en ørefik for at ikke man kjøpte flere aksjer igår.....
- ·1 päivä sittenWhy sis02 in Ireland has come further than most people think. Before SoftOx started today's studies, the company conducted an extensive animal preclinical safety program (toxicology) with the first-generation solution SS0330. This included regulatory GLP studies (Good Laboratory Practice) in two animal species - Göttingen minipigs (up to 14 days with concentrations up to 200 micrograms/mL) and rats (up to 28 days with 1000 micrograms/mL). When a biotech company improves the formulation of a drug during development, a critical question always arises: Must one go back to square one and redo all the expensive and time-consuming animal safety studies, or can one build a scientific "bridge" that allows the company to reuse the work already done? In SoftOx, this bridge is about the transition from the first-generation solution (SS0330) to today's more stable second-generation solution (SS0331 / SIS 2.0). In December 2023, SoftOx obtained formal Scientific Advice from the Danish Medicines Agency (DKMA) to adapt the clinical and non-clinical strategy to this transition. They gave the green light, in addition, partners in the COUNTERACT consortium from summer 2024 have conducted new efficacy studies in the laboratory and in animals (respiratory tract models in mice and rats) with the second-generation solution, where the half-year report for 2026 (p. 22) confirms completed in vitro and in vivo respiratory studies before 2026. The reading of SIS-02 and SIS-03 in the first half of 2027 will therefore be a connection point for work already done, rather than the starting gun for an entirely new preclinical round. When in H1 2027 one gets the answer on which dose human lungs can tolerate in SIS-02 (after the dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.Fresh US patents and heavy FDA expertise in place Digging into American patent registers, one can see that SoftOx's wholly owned IP company WIAB Water Innovation AB has been granted several US patents in 2025–2026. Most interesting is US Patent 12,611,425 (issued April 28, 2026, applied for in August 2023 – the work was presented at the US military's MHSRS symposium in Florida). While current studies test the ready-mixed second-generation liquid (with over two years of shelf life), this patent covers a storage-stable dry-matter precursor (tablet/granulate dissolved in liquid right before use, providing active hypochlorous acid in seconds). For military emergency stockpiles and field use – where low weight and long shelf life without a cold chain are crucial – and for American industrial partners requiring solid IP protection in the US, this is an important piece. Adding together the completed preclinical work, GMP production, American patent protection, and last autumn's recruitment of Dr. Bruce Montgomery (the man who led the FDA-approved inhalation antibiotics TOBI® and Cayston® through approval and sale to Gilead) as head of the Clinical Advisory Board, "phase 1" becomes a far too narrow description of what has actually been built up. H1 2027 as a connection point – not a starting line My hypothesis is therefore that the readout of SIS-02 and SIS-03 in the first half of 2027 will be a connection point for work already performed, rather than the starting shot for an entirely new preclinical round. When the definitive answer to what dose human lungs can tolerate in SIS-02 is obtained in H1 2027 (after dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.
- ·1 päivä sittenWhen does this turn around? The bottom is well reached soon or?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 056 | ||
| 99 427 | ||
| 90 000 | ||
| 270 000 | ||
| 270 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 23.9. | ||
2026 Q1 - tulosraportti 24.6. | ||
2025 Q4 - tulosraportti 25.3. | ||
2025 Q3 - tulosraportti 26.11.2025 | ||
2025 Q2 - tulosraportti 17.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·Alle minuutti sittenWishing everyone a nice day and week, good luck with softox and otherwise in the stock market and life in general, a little patience and I think this stock will come like a shot, keep it up and good luck❤️💪🌞
- ·18 t sittenSoftOx has already completed an extensive preclinical program, including GLP safety studies in two animal species. Recent respiratory studies in the laboratory and animals have also been completed, and GMP production of study medication is established. There are thus several years of development work behind the current studies. SIS-02 in Ireland is investigating safety and tolerability in healthy volunteers and started dosing in June 2026. SIS-03 completed dose escalation the same month with no reported serious adverse events, and the first patient was dosed in August. The company expects data readouts from both studies in the first half of 2027. In addition, the company has been granted a US patent for the dry matter precursor and brought in Bruce Montgomery, with experience from TOBI and Cayston, as head of the clinical advisory committee. H1 2027 could be an important milestone where new human data are evaluated together with existing animal data, manufacturing and patent protection. Positive results could strengthen the basis for partnerships.then we are on our way up towards 0.135 again, now there were no more stoplosses to fish for under 0.11, therefore today's great rise. gi seg selv en ørefik for at ikke man kjøpte flere aksjer igår.....
- ·1 päivä sittenWhy sis02 in Ireland has come further than most people think. Before SoftOx started today's studies, the company conducted an extensive animal preclinical safety program (toxicology) with the first-generation solution SS0330. This included regulatory GLP studies (Good Laboratory Practice) in two animal species - Göttingen minipigs (up to 14 days with concentrations up to 200 micrograms/mL) and rats (up to 28 days with 1000 micrograms/mL). When a biotech company improves the formulation of a drug during development, a critical question always arises: Must one go back to square one and redo all the expensive and time-consuming animal safety studies, or can one build a scientific "bridge" that allows the company to reuse the work already done? In SoftOx, this bridge is about the transition from the first-generation solution (SS0330) to today's more stable second-generation solution (SS0331 / SIS 2.0). In December 2023, SoftOx obtained formal Scientific Advice from the Danish Medicines Agency (DKMA) to adapt the clinical and non-clinical strategy to this transition. They gave the green light, in addition, partners in the COUNTERACT consortium from summer 2024 have conducted new efficacy studies in the laboratory and in animals (respiratory tract models in mice and rats) with the second-generation solution, where the half-year report for 2026 (p. 22) confirms completed in vitro and in vivo respiratory studies before 2026. The reading of SIS-02 and SIS-03 in the first half of 2027 will therefore be a connection point for work already done, rather than the starting gun for an entirely new preclinical round. When in H1 2027 one gets the answer on which dose human lungs can tolerate in SIS-02 (after the dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.Fresh US patents and heavy FDA expertise in place Digging into American patent registers, one can see that SoftOx's wholly owned IP company WIAB Water Innovation AB has been granted several US patents in 2025–2026. Most interesting is US Patent 12,611,425 (issued April 28, 2026, applied for in August 2023 – the work was presented at the US military's MHSRS symposium in Florida). While current studies test the ready-mixed second-generation liquid (with over two years of shelf life), this patent covers a storage-stable dry-matter precursor (tablet/granulate dissolved in liquid right before use, providing active hypochlorous acid in seconds). For military emergency stockpiles and field use – where low weight and long shelf life without a cold chain are crucial – and for American industrial partners requiring solid IP protection in the US, this is an important piece. Adding together the completed preclinical work, GMP production, American patent protection, and last autumn's recruitment of Dr. Bruce Montgomery (the man who led the FDA-approved inhalation antibiotics TOBI® and Cayston® through approval and sale to Gilead) as head of the Clinical Advisory Board, "phase 1" becomes a far too narrow description of what has actually been built up. H1 2027 as a connection point – not a starting line My hypothesis is therefore that the readout of SIS-02 and SIS-03 in the first half of 2027 will be a connection point for work already performed, rather than the starting shot for an entirely new preclinical round. When the definitive answer to what dose human lungs can tolerate in SIS-02 is obtained in H1 2027 (after dose escalation in SIS-03 was already completed without serious adverse events in June 2026) and clinical signals in patients in SIS-03, these human data can be linked directly to the existing package of animal data, manufacturing, and patents. A partner or defense financier does not need to wait for a fully approved drug; the value lies in entering a program where technical, regulatory, and biological risk is already substantially reduced.
- ·1 päivä sittenWhen does this turn around? The bottom is well reached soon or?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 056 | ||
| 99 427 | ||
| 90 000 | ||
| 270 000 | ||
| 270 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt